Cardiotoxicity induced by the combination therapy of chloroquine and azithromycin in human embryonic stem cell-derived cardiomyocytes |
Kim, Ye Seul
(Department of Physiology, School of Medicine, Pusan National University)
Lee, Soo Yong (Division of Cardiology, Department of Internal Medicine and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine) Yoon, Jung Won (Department of Physiology, School of Medicine, Pusan National University) Kim, Dasol (Department of Physiology, School of Medicine, Pusan National University) Yu, Sangbin (Department of Physiology, School of Medicine, Pusan National University) Kim, Jeong Su (Division of Cardiology, Department of Internal Medicine and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine) Kim, Jae Ho (Department of Physiology, School of Medicine, Pusan National University) |
1 | Savarino A, Boelaert JR, Cassone A, Majori G and Cauda R (2003) Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis 3, 722-727 DOI |
2 | Savarino A, Di Trani L, Donatelli I, Cauda R and Cassone A (2006) New insights into the antiviral effects of chloroquine. Lancet Infect Dis 6, 67-69 DOI |
3 | Vincent MJ, Bergeron E, Benjannet S et al (2005) Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2, 69 DOI |
4 | Wang M, Cao R, Zhang L et al (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30, 269-271 DOI |
5 | Yao X, Ye F, Zhang M et al (2020) In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis 71, 732-739 DOI |
6 | Gautret P, Lagier JC, Parola P et al (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 56, 105949 DOI |
7 | Pillat MM, Kruger A, Guimaraes LMF et al (2020) Insights in chloroquine action: perspectives and implications in Malaria and COVID-19. Cytometry A 97, 872-881 DOI |
8 | Colson P, Rolain JM and Raoult D (2020) Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents 55, 105923 DOI |
9 | Satarker S, Ahuja T, Banerjee M et al (2020) Hydroxychloroquine in COVID-19: Potential mechanism of action against SARS-CoV-2. Curr Pharmacol Rep 6, 203-211 DOI |
10 | Das S, Bhowmick S, Tiwari S and Sen S (2020) An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19). Clin Drug Investig 40, 591-601 DOI |
11 | Boulware DR, Pullen MF, Bangdiwala AS et al (2020) A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med 383, 517-525 DOI |
12 | Chatre C, Roubille F, Vernhet H, Jorgensen C and Pers YM (2018) Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature. Drug Saf 41, 919-931 DOI |
13 | White NJ (2007) Cardiotoxicity of antimalarial drugs. Lancet Infect Dis 7, 549-558 DOI |
14 | Min JY and Jang YJ (2012) Macrolide therapy in respiratory viral infections. Mediators Inflamm 2012, 649570 |
15 | Cheng DK, Tung L and Sobie EA (1999) Nonuniform responses of transmembrane potential during electric field stimulation of single cardiac cells. Am J Physiol 277, H351-362 |
16 | Satsuka A and Kanda Y (2020) Cardiotoxicity Assessment of Drugs Using Human iPS Cell-Derived Cardiomyocytes: Toward Proarrhythmic Risk and Cardio-Oncology. Curr Pharm Biotechnol 21, 765-772 DOI |
17 | Sharma A, McKeithan WL, Serrano R et al (2018) Use of human induced pluripotent stem cell-derived cardiomyocytes to assess drug cardiotoxicity. Nat Protoc 13, 3018-3041 DOI |
18 | Thomson JA, Itskovitz-Eldor J, Shapiro SS et al (1998) Embryonic stem cell lines derived from human blastocysts. Science 282, 1145-1147 DOI |
19 | Rast G, Weber J, Disch C, Schuck E, Ittrich C and Guth BD (2015) An integrated platform for simultaneous multiwell field potential recording and Fura-2-based calcium transient ratiometry in human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes. J Pharmacol Toxicol Methods 75, 91-100 DOI |
20 | Inciardi RM, Lupi L, Zaccone G et al (2020) Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 5, 819-824 DOI |
21 | Sala S, Peretto G, Gramegna M et al (2020) Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection. Eur Heart J 41, 1861-1862 DOI |
22 | Tavazzi G, Pellegrini C, Maurelli M et al (2020) Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail 22, 911-915 DOI |
23 | Sirenko O, Crittenden C, Callamaras N et al (2013) Multiparameter in vitro assessment of compound effects on cardiomyocyte physiology using iPSC cells. J Biomol Screen 18, 39-53 DOI |
24 | Traebert M, Dumotier B, Meister L, Hoffmann P, Dominguez-Estevez M and Suter W (2004) Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells. Eur J Pharmacol 484, 41-48 DOI |
25 | Lian X, Zhang J, Azarin SM et al (2013) Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/beta-catenin signaling under fully defined conditions. Nat Protoc 8, 162-175 DOI |
26 | Mubagwa K (2020) Cardiac effects and toxicity of chloroquine: a short update. Int J Antimicrob Agents 56, 106057 DOI |
27 | Vicente J, Zusterzeel R, Johannesen L et al (2019) Assessment of Multi-Ion Channel Block in a Phase I Randomized Study Design: Results of the CiPA Phase I ECG Biomarker Validation Study. Clin Pharmacol Ther 105, 943-953 DOI |
28 | Haeusler IL, Chan XHS, Guerin PJ and White NJ (2018) The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review. BMC Med 16, 200 DOI |
29 | Lian X, Hsiao C, Wilson G et al (2012) Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci U S A 109, E1848-1857 DOI |
30 | Tran DH, Sugamata R, Hirose T et al (2019) Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A (H1N1)pdm09 virus infection by interfering with virus internalization process. J Antibiot (Tokyo) 72, 759-768 DOI |
31 | Juurlink DN (2014) The cardiovascular safety of azithromycin. CMAJ 186, 1127-1128 DOI |
32 | Tohyama S, Hattori F, Sano M et al (2013) Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. Cell Stem Cell 12, 127-137 DOI |
33 | Scherrmann JM (2020) Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy. AAPS J 22, 86 DOI |
34 | Ohe M, Shida H, Jodo S et al (2020) Macrolide treatment for COVID-19: Will this be the way forward? Biosci Trends 14, 159-160 DOI |
35 | Chorin E, Dai M, Shulman E et al (2020) The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. Nat Med 26, 808-809 DOI |
36 | Ramireddy A, Chugh H, Reinier K et al (2020) Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring. J Am Heart Assoc 9, e017144 |
37 | Mitra RL, Greenstein SA and Epstein LM (2020) An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine. Heart Rhythm Case Rep 6, 244-248 |
38 | Ray WA, Murray KT, Hall K, Arbogast PG and Stein CM (2012) Azithromycin and the risk of cardiovascular death. N Engl J Med 366, 1881-1890 DOI |
39 | Juurlink DN (2020) Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. CMAJ 192, E450-E453 DOI |
40 | Gintant G, Sager PT and Stockbridge N (2016) Evolution of strategies to improve preclinical cardiac safety testing. Nat Rev Drug Discov 15, 457-471 DOI |